ECSP099411A - Derivados de aril sulfamida y métodos para su uso - Google Patents

Derivados de aril sulfamida y métodos para su uso

Info

Publication number
ECSP099411A
ECSP099411A EC2009009411A ECSP099411A ECSP099411A EC SP099411 A ECSP099411 A EC SP099411A EC 2009009411 A EC2009009411 A EC 2009009411A EC SP099411 A ECSP099411 A EC SP099411A EC SP099411 A ECSP099411 A EC SP099411A
Authority
EC
Ecuador
Prior art keywords
disorders
derivatives
methods
sulfamida
aril
Prior art date
Application number
EC2009009411A
Other languages
English (en)
Inventor
Charles William Mann
Andrew Fensome
Puwen Zhang
Eugene Anthony Terefenko
Callain Younghee Kim
An Thien Vu
Stephen Todd Cohn
Eugente John Trybulski
Joseph Peter Sabatucci
Paige Erin Mahaney
Douglas John Jenkins
Casey Cameron Mccomas
Michael Anthony Marella
Richard Page Woodworth
Joel Adam Goldberg
David John O'neill
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP099411A publication Critical patent/ECSP099411A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se dirige a derivados de aril sulfamida de la fórmula I; o una sal farmacéuticamente aceptable, estereoisómero o tautómero de estos, que son inhibidores de recaptación de monoamina, composiciones que contienen estos derivados, y métodos para su uso para la prevención y tratamiento de afecciones, que incluyen, inter alia, síntomas vasomotrices, disfunción sexual, trastornos gastrointestinales y trastorno genitourinario, trastornos depresivos, trastornos de comportamiento endogéno, trastornos cognitivos, neuropatía diabética, dolor, y otros enfermedades y trastornos.
EC2009009411A 2006-12-12 2009-06-12 Derivados de aril sulfamida y métodos para su uso ECSP099411A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86964406P 2006-12-12 2006-12-12

Publications (1)

Publication Number Publication Date
ECSP099411A true ECSP099411A (es) 2009-07-31

Family

ID=39273293

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009411A ECSP099411A (es) 2006-12-12 2009-06-12 Derivados de aril sulfamida y métodos para su uso

Country Status (20)

Country Link
US (4) US20080161366A1 (es)
EP (1) EP2061776A1 (es)
JP (1) JP2010512401A (es)
KR (1) KR20090087506A (es)
CN (1) CN101600701A (es)
AR (1) AR064318A1 (es)
AU (1) AU2007333593A1 (es)
BR (1) BRPI0720289A2 (es)
CA (1) CA2671844A1 (es)
CL (1) CL2007003590A1 (es)
CR (1) CR10866A (es)
EC (1) ECSP099411A (es)
MX (1) MX2009006359A (es)
NO (1) NO20092092L (es)
PE (1) PE20081395A1 (es)
RU (1) RU2009121017A (es)
SV (1) SV2009003295A (es)
TW (1) TW200843753A (es)
WO (1) WO2008073459A1 (es)
ZA (1) ZA200904109B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156826A1 (en) * 2007-12-12 2009-06-18 Wyeth Methods for the preparation of hydroxy-substituted aryl sulfamide compounds
GB0813694D0 (en) * 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
AU2011223898A1 (en) * 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
CN102838567B (zh) * 2011-06-23 2014-12-31 深圳市湘雅生物医药研究院 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途
US9205085B2 (en) 2011-11-07 2015-12-08 Emory University Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
US9867813B2 (en) * 2015-11-17 2018-01-16 Thomas Daly Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy
CN107337616A (zh) * 2017-07-13 2017-11-10 上海昕盛医药科技有限公司 一种盐酸班布特罗杂质f的合成方法
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
IL279476B2 (en) 2018-06-21 2024-04-01 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
CN116003261A (zh) * 2022-12-19 2023-04-25 江苏康恒化工有限公司 新型聚氨酯扩链剂2-氨基-2’-氯二苯胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177221A (en) * 1963-02-05 1965-04-06 Mcneilab Inc 2, 1, 3-benzothiadiazoline-2, 2-dioxides
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
ZA966885B (en) * 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
GB9825413D0 (en) * 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
RU2317988C2 (ru) * 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
AU2002303406B2 (en) 2001-04-18 2006-03-30 Euro-Celtique S.A. Nociceptin analogs
MXPA04006344A (es) * 2001-12-28 2005-03-31 Takeda Pharmaceutical Preventivos/remedios para la perturbacion de miccion.
JP2008539220A (ja) * 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
KR20080050453A (ko) * 2005-09-29 2008-06-05 와이어쓰 모노아민 재흡수에 의해 개선되는 질병의 치료에 사용하기위한 벤조티아디아졸릴페닐알킬아민 유도체

Also Published As

Publication number Publication date
SV2009003295A (es) 2009-10-29
RU2009121017A (ru) 2011-01-20
PE20081395A1 (es) 2008-09-17
US20100029641A1 (en) 2010-02-04
BRPI0720289A2 (pt) 2014-02-04
CN101600701A (zh) 2009-12-09
MX2009006359A (es) 2009-06-26
CA2671844A1 (en) 2008-06-19
NO20092092L (no) 2009-08-19
US7601722B2 (en) 2009-10-13
JP2010512401A (ja) 2010-04-22
US20080161366A1 (en) 2008-07-03
TW200843753A (en) 2008-11-16
AR064318A1 (es) 2009-03-25
CL2007003590A1 (es) 2008-02-29
AU2007333593A1 (en) 2008-06-19
ZA200904109B (en) 2010-04-28
US20080167303A1 (en) 2008-07-10
WO2008073459A1 (en) 2008-06-19
KR20090087506A (ko) 2009-08-17
EP2061776A1 (en) 2009-05-27
US20080194654A1 (en) 2008-08-14
CR10866A (es) 2009-07-14

Similar Documents

Publication Publication Date Title
ECSP099411A (es) Derivados de aril sulfamida y métodos para su uso
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201170161A1 (ru) 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201690391A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
EA200801738A1 (ru) Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
EA201370208A1 (ru) Формы рифаксимина и их применение
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
ATE517882T1 (de) Chinolinderivate
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
EA201290329A1 (ru) Селективные гетрероциклические модуляторы рецептора сфингозин-1-фосфата
NI202100012A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
BRPI0713743C1 (pt) composto, e, composição farmacêutica
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт